351 related articles for article (PubMed ID: 16759774)
1. Allogeneic transplantation for myelodysplastic syndrome (MDS).
Ingram W; Lim ZY; Mufti GJ
Blood Rev; 2007 Mar; 21(2):61-71. PubMed ID: 16759774
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic stem cell transplantation for myelodysplastic syndrome.
Barrett AJ; Savani BN
Semin Hematol; 2008 Jan; 45(1):49-59. PubMed ID: 18179969
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
6. Transplantation strategies for the management of patients with myelodysplastic syndromes.
Meletis J; Terpos E
J BUON; 2009; 14(4):551-64. PubMed ID: 20148443
[TBL] [Abstract][Full Text] [Related]
7. Hemopoietic cell transplantation for the myelodysplastic syndromes.
Scott BL; Deeg HJ
Arch Immunol Ther Exp (Warsz); 2005; 53(4):297-307. PubMed ID: 16088314
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
[TBL] [Abstract][Full Text] [Related]
9. The evolution of hematopoietic SCT in myelodysplastic syndrome.
Kindwall-Keller T; Isola LM
Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome.
de Lima M; Giralt S
Semin Hematol; 2006 Apr; 43(2):107-17. PubMed ID: 16616044
[TBL] [Abstract][Full Text] [Related]
11. [Alloreactive donor lymphocytes (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT): study of toxicity and efficacy].
Michallet AS; Nicolini F; Michallet M
Bull Cancer; 2003; 90(8-9):758-62. PubMed ID: 14609766
[TBL] [Abstract][Full Text] [Related]
12. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
13. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic transplantation of haematopoietic progenitors for myelodysplastic syndromes and myeloproliferative disorders.
Locatelli F; Giorgiani G; Comoli P
Bone Marrow Transplant; 1998 Apr; 21 Suppl 2():S17-20. PubMed ID: 9630318
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic stem cell transplantation for myelodysplastic syndrome.
Parmar S; de Lima M
Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S37-44. PubMed ID: 19857589
[TBL] [Abstract][Full Text] [Related]
16. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.
Valcárcel D; Martino R
Curr Opin Oncol; 2007 Nov; 19(6):660-6. PubMed ID: 17906468
[TBL] [Abstract][Full Text] [Related]
17. [Mini-transplant for acute myeloblastic leukemia and myelodysplastic syndrome].
Kanda Y
Nihon Rinsho; 2003 Sep; 61(9):1565-72. PubMed ID: 14515725
[TBL] [Abstract][Full Text] [Related]
18. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
Zhang Z; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
[TBL] [Abstract][Full Text] [Related]
19. Autologous and allogeneic stem cell transplantation for myelodysplastic syndrome.
de Witte T; Oosterveld M; Muus P
Blood Rev; 2007 Jan; 21(1):49-59. PubMed ID: 16822600
[TBL] [Abstract][Full Text] [Related]
20. Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation.
Loren AW; Porter DL
Curr Opin Oncol; 2006 Mar; 18(2):107-14. PubMed ID: 16462177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
